» Articles » PMID: 36270950

Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings

Abstract

A woman presented at age 18 years with partial myelitis and diplopia and experienced multiple subsequent relapses. Her MRI demonstrated T2 abnormalities characteristic of multiple sclerosis (MS) (white matter ovoid lesions and Dawson fingers), and CSF demonstrated an elevated IgG index and oligoclonal bands restricted to the CSF. Diagnosed with clinically definite relapsing-remitting MS, she was treated with various MS disease-modifying therapies and eventually began experiencing secondary progression. At age 57 years, she developed an acute longitudinally extensive transverse myelitis and was found to have AQP4 antibodies by cell-based assay. Our analysis of the clinical course, radiographic findings, molecular diagnostic methods, and treatment response characteristics support the hypothesis that our patient most likely had 2 CNS inflammatory disorders: MS, which manifested as a teenager, and neuromyelitis optica spectrum disorder, which evolved in her sixth decade of life. This case emphasizes a key principle in neurology practice, which is to reconsider whether the original working diagnosis remains tenable, especially when confronted with evidence (clinical and/or paraclinical) that raises the possibility of a distinctively different disorder.

References
1.
Pittock S, Lennon V, Bakshi N, Shen L, McKeon A, Quach H . Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol. 2014; 71(11):1433-6. DOI: 10.1001/jamaneurol.2014.1581. View

2.
Anadani N, Hyland M, Cruz R, Lisak R, Costello K, Major E . Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2021; 8(1). PMC: 7803340. DOI: 10.1212/NXI.0000000000000929. View

3.
Edwards L, Constantinescu C . A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004; 10(5):575-81. DOI: 10.1191/1352458504ms1087oa. View

4.
Marrie R, Reider N, Cohen J, Stuve O, Sorensen P, Cutter G . A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2014; 21(3):282-93. PMC: 4429166. DOI: 10.1177/1352458514564490. View

5.
Wattjes M, Ciccarelli O, Reich D, Banwell B, De Stefano N, Enzinger C . 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021; 20(8):653-670. DOI: 10.1016/S1474-4422(21)00095-8. View